Robert Ford, Chairman and CEO of Abbott Labs, shares insights on the company’s innovative glucose monitoring technology and diversification strategies. Rob Davis of Merck discusses their promising oncology pipeline and the significance of Gardasil amidst challenges. Len Schleifer from Regeneron Pharmaceuticals highlights their focus on groundbreaking drug development and long-term vision in healthcare. Together, they explore the evolving landscape of the pharmaceutical industry and the impact of innovation on market dynamics.

Merck CEO Rob Davis discusses the approval of Winrevair for high blood pressure. Topics include FDA approval, strategic portfolio diversification for diseases like fatty liver, and analysis of healthcare costs and drug pricing disparities between the US, Europe, and the UK.